Some of the most exciting innovation in clinical medicine is occurring at the convergence of medicine and technology. At Intarcia, this is our 'sweet spot.'
In Research & Development, our drug development expertise is our key competitive advantage. This is demonstrated by our ability to stabilize therapeutic proteins, peptides and antibody fragments, and to deliver them in a constant and consistent manner over an extended period of time via our unique and proprietary subcutaneous drug-delivery system.
Our most advanced product candidate is ITCA 650 for the treatment of Type 2 Diabetes. Currently planned to commence enrollment for a global Phase 3 clinical study in early 2013, the investigational therapy holds promise to be an important treatment in this increasingly common and important disease. Learn more about ITCA 650
Intarcia's lead product candidate, ITCA 650 is being developed for the treatment of Type 2 Diabetes and employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy.
Type 2 Diabetes is the most common form of diabetes, and is triggered by a combination of risk factors that include older age, obesity, family history, having diabetes while pregnant, a sedentary lifestyle and race/ethnicity.2
Currently, 1 in 10 Americans have type 2 diabetes and 25 percent of them do not even know it. According to a 2010 report from the Centers for Disease Control and Prevention (CDC), 1 in 3 people in the U.S. will have type 2 diabetes by 2050 if current trends continue. As a result of the increasing prevalence of the disease, diabetes alone could account for about one one-tenth of the nation's healthcare billsapproximately $500 billion annually.3